Mochida Pharmaceutical Co., Ltd. (MFY.F)

18.90 +0.10 (+0.53%) As of 08:49AM CEST. Market open.

Mochida Pharmaceutical Co., Ltd.

7, Yotsuya 1-chome
Shinjuku-ku
Tokyo 160-8515
Japan
81 3 3358 7211
https://www.mochida.co.jp

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 1,529

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Naoyuki Mochida	President & Representative Director	N/A	N/A	N/A
Masayoshi Takeda	GM, Head of Finance & Accounting Department and Full-Time Audit & Supervisory Board Member	N/A	N/A	N/A
Masaaki Yokosuka	Executive Officer, GM and Head of Legal & Compliance Department	N/A	N/A	N/A
Junichi Makino	Executive Officer, GM & Head of Human Resources Department	N/A	N/A	N/A
Keiichi Sagisaka	Senior Executive Managing Officer of Pharmaceutical Business & Healthcare and Director	N/A	N/A	N/A
Chu Sakata	Senior EVP & Representative Director	N/A	N/A	N/A
Kiyoshi Mizuguchi Ph.D.	Exec Managing Officer of Research & Development, Supervisor of Pharmaceutical Plant and Director	N/A	N/A	N/A
Junichi Sakaki Ph.D.	Senior Exec Managing Officer of Business Development, Supervisor of Biomaterials Business & Director	N/A	N/A	N/A
Kazumasa Fukuchi	Head of Pharmaceutical Business Division	N/A	N/A	N/A
Yutaka Kawakami Ph.D.	Executive Managing Officer, Executive Officer, Head of RA, QA & PV and Executive Director	N/A	N/A	N/A

Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Mochida Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals and healthcare products in Japan. The company offers pharmaceuticals products for the treatment of cardiovascular, obstetrics, gynecology, dermatology, psychiatry, and gastroenterology. It offers Lialda for the treatment of ulcerative colitis; Goofice and Movicol for the treatment of chronic constipation; Lexapro, an antidepressant drug; Epadel drug for hyperlipidemia and arteriosclerosis obliterans; Urece for the treatment of gout and hyperuricemia; and Treprost for the treatment of pulmonary arterial hypertension. In addition, the company provides Atelec to treat calcium channel blocker with a long-acting hypotensive effect; Tramcet, an analgesic for chronic pain and pain after tooth extraction; Heparin Sodium MOCHIDA, an anticoagulant agent; Beselna, a therapeutic agent for condyloma acuminatum and actinic keratosis; and Dinagest, a therapeutic agent for endometriosis, adenomyosis, and dysmenorrhea. Further it offers skin care, baby care, personal care, and nursing products. Additionally, the company develops mesalazine, ethyl icosapentate, daridorexant, dotinurad, and treprostinil drugs for the treatment of ulcerative colitis, hypertriglyceridemia, insomnia, gout and hyperuricemia, and pulmonary hypertension associated with interstitial lung disease; and dMD-001, a medical device that is used for the treatment of articular cartilage lesions, as well as dMD-002, which is used for the treatment of cavernous nerve injury. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Tokyo, Japan.

Corporate Governance

Mochida Pharmaceutical Co., Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.